Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients - PACE-CME

Residual inflammatory risk is major driver of CV events and mortality in statintreated patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Imaging study with PCSK9 inhibitor in patients with stable CAD
Imaging study with PCSK9 inhibitor in patients with stable CAD
ACC.23
Imaging study with PCSK9 inhibitor in patients with stable CAD
- Annapoorna Kini, MD
Do personalized reminders to clinicians result in higher use of high-intensity statins?
Do personalized reminders to clinicians result in higher use of high-intensity statins?
ACC.23
Do personalized reminders to clinicians result in higher use of high-intensity statins?
- Prof. Salim Virani, MD, PhD
Implementing precision health for public health using causal AI
Implementing precision health for public health using causal AI
ACC.23
Implementing precision health for public health using causal AI
- Ami Bhatt, MD
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
ACC.23
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
- Deepak Bhatt, MD